TB Drug Accelerator (TBDA) Program

At a Glance
  • Status: Active Consortium
  • Year Launched: 2012
  • Initiating Organization: BGMF
  • Initiator Type: Nonprofit foundation
  • Rare disease
  • Disease focus:
    Tuberculosis
  • Location: International

Abstract

The TB Drug Accelerator (TBDA) Program targets the discovery of new TB drugs by collaborating on early-stage research. The long-term goal of the TBDA Program is to create a tuberculosis (TB) drug regimen that cures patients in only one month, rather than the six months now needed for treatment.

Mission

The TBDA Program aims to develop five new preclinical drug candidates with treatment-shortening potential within five years and proof of concept for a one-month, three-drug regimen within 10 years.

Consortium History

April 2012: TBDA Program launched

Financing

The program is supported by $20 million from the Bill & Melinda Gates Foundation.

Sponsors & Partners

AbbVie

AstraZeneca

Bayer HealthCare

Bill & Melinda Gates Foundation

Eisai

Eli Lilly and Company

GlaxoSmithKline

MSD

Sanofi

Global Alliance for TB Drug Development (TB Alliance)

Infectious Disease Research Institute

Texas A&M University

US National Institutes of Health

Weill Medical College

Cornell University


Last Updated: 04/08/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.